Pharmanova Specialties Private Limited - Due diligence report

A 360° intelligence report on Pharmanova Specialties Private Limited: trust score, financial health, credit view, compliance, directors, gro…

2014-01-31 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
PS Pharmanova Specialties Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pharmanova Specialties Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
59/100
Trust Score
Moderate

Pharmanova Specialties Private Limited is assessed as Moderate with a Trust Score of 59/100. Pharmanova Specialties Private Limited is an active private limited indian non-government company incorporated in 2014, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 12 Aug 2026 from the latest processed filings. Pharmanova Specialties Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
59/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
57/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
15/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 1 satisfied (7.15 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Compliance Score: 57/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • 1 auditor resignation(s) filed - latest: B.M. MEHTA AND COMPANY (PROPRIETOR ASHIT MEHTA) on 2018-07-12.
  • Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MANEESH RAMAKANT SAPTE 01234567 Director 01/04/2018 6 yrs Approved
PRASENJIT AJIT MUKHERJEE 01234567 Director 01/04/2018 6 yrs Approved
VINAY RAMAKANT SAPTE 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Maneesh Pharmaceuticals Limited
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 7 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Maneesh Pharmaceuticals Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 60
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Negative net worth.
Statutory filings appear overdue.
Compliance score is weak (57/100).
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 4.43 Lakh.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence58/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment39/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view38/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
11 Jul 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
17 Sep 2022
Securities allotted
5150000 Equity Shares - 5.15 cr raised
31 Mar 2021
Share transfer (FY 2021)
3300.00000000 shares to Maneesh Phamaceuticals Limited
Share transfer (FY 2021)
6000.00000000 shares to Maneesh Phamaceuticals Limited
31 Mar 2020
Share transfer (FY 2020)
4000.00000000 shares to Maneesh Pharmaceuticals Limited
Share transfer (FY 2020)
3700.00000000 shares to Maneesh Pharmaceuticals Limited
24 Oct 2019
Director appointed
PRASENJIT AJIT MUKHERJEE (Director)
21 Aug 2019
Charge satisfied
Others
20 Aug 2019
Director appointed
MANEESH RAMAKANT SAPTE (Director)
Director appointed
VINAY RAMAKANT SAPTE (Director)
Director ceased
KAMLESH SHAH
Director ceased
JIGAR KAMLESH SHAH
Director ceased
HARDIK KAMLESH SHAH
31 Mar 2019
Share transfer (FY 2019)
3000.00000000 shares to Prasenjit Ajit Mukherjee
10

Key Observations

Auto-generated from the data above
Revenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Integrated Fire Protection Pvt Ltd U24292WB1984PTC037286 Kolkata, West Bengal, India
Shirdi Organics Private Limited U24232UR2011PTC009918 Rudrapur, Uttarakhand, India
Rahul Engineering Global Private Limited U29297PN2021PTC204681 Pune, Maharashtra, India
Redox Industries Limited U24120GJ2008PLC053173 Ahmedabad, Gujarat, India
Pranami Drugs Private Limited U24231GJ2002PTC041544 Ankleshwar, Gujarat, India
Shreenath Metchem Private Limited U51900MH1988PTC049969 Mumbai, Maharashtra, India
Acme Diet Care Private Limited U24231GJ2002PTC040372 Dist Ahmedabad, Gujarat, India
Orablue Chem Private Limited U24110GJ2016PTC086466 Morbi, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pharmanova Specialties Private Limited before audits and certifications: compliance score 57/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pharmanova Specialties Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 45/100, margin trends, ownership structure and peer set for Pharmanova Specialties Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 59/100, distress signals and MSME payment-delay disclosures - know whether Pharmanova Specialties Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Pharmanova Specialties Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pharmanova Specialties Private Limited an active company?

Pharmanova Specialties Private Limited has MCA status “Active” with a compliance score of 57/100 (Moderate).

Is Pharmanova Specialties Private Limited financially healthy?

Pharmanova Specialties Private Limited has a Financial Health Score of 15/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Pharmanova Specialties Private Limited?

Its overall Trust Score is 59/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pharmanova Specialties Private Limited?

The ultimate holding entity is Maneesh Pharmaceuticals Limited. 3 active director(s) are on record.

Does Pharmanova Specialties Private Limited have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Pharmanova Specialties Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 57/100 (Moderate).

Is it risky to lend to Pharmanova Specialties Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.